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Abstract The serotonergic system of the brain is complex,
with an extensive innervation pattern covering all brain
regions and endowed with at least 15 different receptors
(each with their particular distribution patterns), specific
reuptake mechanisms and synthetic processes. Many
aspects of the functioning of the serotonergic system are
still unclear, partially because of the difficulty of measuring
physiological processes in the living brain. In this review
we give an overview of the conventional methods of
measuring serotonin synthesis and methods using positron
emission tomography (PET) tracers, more specifically with
respect to serotonergic function in affective disorders.
Conventional methods are invasive and do not directly
measure synthesis rates. Although they may give insight
into turnover rates, a more direct measurement may be
preferred. PET is a noninvasive technique which can trace
metabolic processes, like serotonin synthesis. Tracers






HTP). Both tracers have advantages and disadvantages.
[
11C]AMT can enter the kynurenine pathway under inflam-
matory conditions (and thus provide a false signal), but this
tracer has been used in many studies leading to novel
insights regarding antidepressant action. [
11C]5-HTP is
difficult to produce, but trapping of this compound may
better represent serotonin synthesis. AMT and 5-HTP
kinetics are differently affected by tryptophan depletion
and changes of mood. This may indicate that both tracers
are associated with different enzymatic processes. In
conclusion, PET with radiolabelled substrates for the
serotonergic pathway is the only direct way to detect
changes of serotonin synthesis in the living brain.





Serotonergic innervations are widely spread throughout the
brain with cell bodies of origin lying in the dorsal (DRN) or
median (MRN) raphe nucleus, and a column of raphe nuclei
in lower brainstem regions, projecting to basically all
divisions of the brain and spinal cord (Fig. 1). Synthesis
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DOI 10.1007/s00259-010-1663-2of serotonin (5-HT) takes place within neurons and
especially in serotonergic terminals, and this process
includes two enzymatic steps. The first step is the
conversion of the precursor molecule, the amino acid
tryptophan (Trp), to 5-hydroxytryptophan (5-HTP) by
tryptophan hydroxylase (TPH) 1 or 2. The second step in
the production of 5-HT involves the enzymatic action of
aromatic amino acid decarboxylase (AADC) that has L-
dopa and 5-HTP as a substrate. 5-HT is eventually
degraded to 5-hydroxyindoleacetic acid (5-HIAA) by
monoamine oxidase (MAO).
After synthesis, 5-HT is transported by the vesicular
monoamine transporter and stored in vesicles at the
neuronal presynaptic endings. When neurons fire, these
vesicles fuse with the synaptic membrane and release 5-HT
into the synaptic cleft. Released 5-HT can bind to many
different receptors, both postsynaptic and presynaptic or be
taken up by the serotonergic reuptake transporter (SERT).
There are at least 15 different 5-HT receptors which are
divided into 7 distinct families (5-HT1–7)[ 1]. Postsynaptic
receptor binding can be either inhibitory or excitatory,
depending on which subtype is stimulated. The presynaptic
receptors (5-HT1A, located somatodendritic, and 5-HT1B,
located on terminals) are autoreceptors that inhibit seroto-
nergic neurotransmission, while heteroreceptors influence
the release of neurotransmitters other than 5-HT [2].
Almost all 5-HT receptors are G protein-coupled (metabo-
tropic), with the exception of the 5-HT3 subtype which is a
ligand-gated ion channel [1].
Different subtypes of the 5-HT receptor are located in
different brain regions and probably regulate different
behavioural functions. An important role of 5-HT is the
regulation of mood, and several 5-HT receptor subtypes
are involved in the actions of antidepressants and
antipsychotics. Serotonin synthesis may be of special
interest because this process is controlled by 5-HT1A
receptors, which are implied in the therapeutic efficacy of
antidepressants [3].
Itisclearthat5-HTinfluencesmanyotherneurotransmitter
systems in an excitatory or inhibitory manner. One important
keyaspectthatregulatesserotonergic neurotransmissionisthe
availability of the 5-HT precursor: the amino acid Trp.
In addition to conversion to serotonin, Trp is metabo-
lized in the kynurenine pathway and used for protein
synthesis. The rate-limiting step in the kynurenine pathway
is the activity of indoleamine 2,3-dioxygenase (IDO) in the
CNS and tryptophan 2,3-dioxygenase in peripheral organs.
Both enzymes convert Trp to kynurenine. Activation of
IDO within the CNS takes place under the influence of
proinflammatory cytokines mainly within microglial cells.
Increased cytokines and IDO activity have been linked to
major depression in depressed subjects and in patients with
inflammatory somatic disorders [4]. Increased IDO activity
under inflammatory conditions may increase the amount of
Trp used in the kynurenine pathway and consequently
reduce the availability of Trp for 5-HT synthesis.
All the above-mentioned aspects of the serotonergic
system may act in concert to enable the organism to
function properly. The question is how can we obtain a
reliable view of ongoing serotonergic processes in the
living brain and what is the contribution of different
receptor subtypes and determinants of 5-HT release (like
its synthesis). Positron Emission Tomography (PET) can
quantify these processes in a noninvasive manner. In
Table 1, the most often used radiotracers to measure aspects
of the serotonin system are listed [5–25]. Such tracers are
reviewed elsewhere in greater detail [26, 27]. As there are
no Single Photon Emission Computed Tomography
Fig. 1 The serotonergic system.
The cell bodies of serotonergic
neurons lay in the brainstem
raphe nuclei. These neurons
project to many brain areas like
the cortex, basal ganglia, cere-
bellum, thalamus, limbic areas
like hippocampus and amygda-
la, and spinal cord. Different 5-
HT receptor subtypes have a
specific distribution in the brain.
Autoreceptors in the raphe nu-
clei are depicted on neuronal
cell bodies (5-HT1A) or in ter-
minal areas and raphe nuclei on
the presynapse (5-HT1B). The
depiction of other 5-HT receptor
subtypes in terminal areas can
either represent heteroreceptors
or postsynaptic receptors on 5-
HT neurons
Eur J Nucl Med Mol Imaging (2011) 38:576–591 577(SPECT) tracers to measure serotonin synthesis, we
mention only PET tracers.
In the present review we will mainly focus on the
quantification of serotonin synthesis and its preclinical and
clinical application using conventional and PET imaging
techniques.
Conventional methods: measuring 5-HT
and its metabolites in platelets and CSF
In early studies of experimental animals, concentrations of 5-
HT and its metabolites in tissue after inhibition of AADC or
MAO were used as an estimate of 5-HT turnover. Inhibiting
MAO results in a decrease of the conversion of 5-HT to 5-
HIAA. By measuring either the reduction of 5-HIAA or the
accumulation of 5-HT, turnover rates of 5-HT can be
estimated. A similar approach is inhibition of the transport
of 5-HIAA over the blood-brain barrier (BBB), from brain to
the circulation. Inhibition of this transport by probenecid
results in 5-HIAA accumulation within the brain, and the
rate of this accumulation is related to the turnover rate of 5-
HT. The accumulation of 5-HTP in the brain after AADC
inhibition with NSD-1015 can be used as a measure for 5-
HT synthesis. Assays of serotonin and its metabolites can be
performed by analysis of tissue homogenates, by micro-
dialysis or by analysis of body fluids (blood, urine or CSF)
[28–30]. Such methods have four major disadvantages: (1) it
is not certain that the target enzymes are fully inhibited under
the conditions of the study, (2) the inhibitors may influence
other physiological processes (for example 5-HT synthesis),
(3) the measurements in plasma and urine include peripheral
processes and (4) these invasive techniques cannot be
applied in humans.








11C]NAD-195 Sandell et al. [22]
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Pike et al. [20]
[
18F]FCWAY Lang et al. [13]
[
18F]MEFWAY Saigal N., Synthesis and biologic evaluation of a novel serotonin 5-
HT1A receptor radioligand, 18F-labeled mefway, in rodents and
imaging by PET in a nonhuman primate, 2006
[
11C]RWAY Yasuno et al. [25]
[
11C]CUMI-101 Kumar et al. [12]
5-HT1B Autoreceptor on nerve terminals/
inhibitory heteroreceptor
[
11C]AZ10419369 Pierson et al. [18]
[
11C]P943 Gallezot et al. [8]
5-HT2A Excitatory receptor (e.g.
regulation gene transcription)
[
18F]setoperone Blin et al. [6]
[
18F]altanserin Lemaire et al. [14]
[
11C]MDL-100907 Lundkvist et al. [15]
[
18F]MH.MZ Herth et al. [10]
5-HT4 Excitatory receptor [
11C]SB207145 Marner et al. [17]
SERT Reuptake transporter (e.g. target
SSRI)
[
11C]McN5652 Suehiro et al. [24]
[
11C]DASB Houle et al. [11]
[
11C]MADAM Halldin et al. [9]
[
18F]ADAM Ma et al. [16]
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578 Eur J Nucl Med Mol Imaging (2011) 38:576–591Turnover rates of 5-HT in humans are usually assessed
by measuring 5-HT content of blood platelets or by
analysis of samples of CSF which are acquired through
lumbar puncture, an uncomfortable and invasive proce-
dure. Usually the ratio of 5-HIAA and 5-HT is measured
and sometimes only 5-HIAA concentrations are used as an
index of 5-HT turnover (because 5-HT concentrations are
negligible compared to 5-HIAA concentrations) [31].
Assays of platelet 5-HT content are of questionable value,
since peripheral processes may not be an accurate
reflection of the corresponding processes in the CNS. In
research focusing on this question contradictory results
were obtained.
Some studies indicate a close relationship between 5-HT
turnover in brain and platelets. There are similarities
between neurons and platelets regarding the mechanisms
of 5-HT transport and the presence of certain binding sites
including the 5-HT2 receptor [32, 33]. For example, rats
show decreased levels of 5-HT both in platelet-rich plasma
and in brain homogenates after the forced swim test (FST),
used to assess antidepressant efficacy. This decrease is
reduced after acute treatment of animals with a selective
serotonin reuptake inhibitor (SSRI) (fluoxetine) and in
naive rats, fluoxetine causes an increase in 5-HT [34]. The
5-HT concentration in brain homogenates after chronic (12
days) treatment of rats with an SSRI was comparable to the
amount found in platelet-rich plasma. The 5-HT concentra-
tion in isolated platelets returned to control levels at day 12,
which may reflect comparable changes in neurons.
In contrast to these positive results, there is also evidence
indicating that 5-HT in platelets and in brain may not
always be changed in parallel. In 5-HT1A receptor knockout
mice, 5-HT concentrations in platelets and in brain show
similar decreases until 2 weeks after birth. After 2 weeks,
however, the 5-HT content of platelets is increased
compared to wild-type mice, whereas brain 5-HT concen-
trations are normalized [34]. In addition, no correlation was
observed between the binding potential of the 5-HT2A
ligand [
18F]setoperone in the brain and binding of [
3H]LSD
in blood platelets of healthy volunteers [35]. This indicates
that extrapolation of measurements in blood platelets to 5-
HT neurotransmission in the brain is difficult. Such
extrapolations must be performed with caution and direct
measurements of 5-HT in the brain should be preferred.
Another alternative for directly measuring brain con-
centrations is measurement of 5-HT and its metabolites
in samples of CSF acquired by lumbar puncture. Because
the levels of 5-HT in CSF are very low (less then 10 pg/
ml), measurements of 5-HT concentration cannot be used
for determination of 5-HT turnover rates [36]. Another
option is measuring 5-HIAA concentrations in CSF,
because 5-HIAA is present in much greater quantities.
Increases of 5-HIAA after inhibition of MAO or of 5-
HIAA transport by probenecid should correlate to the
formation rate of 5-HT. However, this method has also
many drawbacks [31]:
– A lumbar puncture is invasive and often experienced as
unpleasant.
– Measurements of 5-HIAA concentrations will partly
represent the rate of transport of 5-HIAA into the
CSF.
– Because of the high concentrations of 5-HIAA com-
pared to 5-HT, changes in 5-HIAA are only detectable
after a delay of several hours.
– 5-HT concentrations in lumbar CSF are not an accurate
reflection of cerebral 5-HT synthesis, since they
partially reflect synthesis of 5-HT within the spinal
cord. There is a gradient from cisterna magna to spinal
subarachnoid as more 5-HT is synthesized in the brain
than in the spinal cord.
– 5-HIAA is transported from brain and CSF, back into
the bloodstream.
The last process can be inhibited by administration of
probenecid, which blocks the active transport of acidic
metabolites out of the brain and CSF. Measurements of 5-
HIAA in CSF and the “probenecid test” were frequently
used by Van Praag and Korf [37]. Concentrations of 5-
HIAA were measured in the CSF at baseline and after
administration of probenecid. By using this method they
were one of the pioneers linking serotonin deficiency to
depressive symptoms and proposed the “predisposition
hypothesis” which is partially maintained even today. The
increase of 5-HIAA concentrations after probenecid was
lower in depressive patients compared to the control group.
This indicates involvement of 5-HT in depression. The
predisposition hypothesis was further based on different
findings. A higher frequency of depression was observed in
patients with 5-HT deficiency and this deficiency in 5-HT
persisted even after a depressive episode. Additionally, the
use of 5-HTP as a prophylactic agent reduced the rates of
relapse in depressed patients [38, 39].
A recent study reported that 5-HIAA in the blood of
patients with major depression, using a jugular vein
catheter, were actually increased, suggesting increased 5-
HT turnover. This increase in 5-HIAA was reduced by
SSRI treatment and dependent on the s and l allele
polymorphisms of SERT [40]. This result conflicts with
assumptions that 5-HT synthesis is decreased in depressed
patients and that antidepressants cause an increase in 5-HT
signal transduction. A possibility is that SSRIs influence 5-
HT synthesis differently under acute and chronic circum-
stances, but they could also indirectly influence breakdown
of 5-HT by MAO resulting in decreased turnover. SSRIs
may increase extracellular 5-HT concentrations and con-
Eur J Nucl Med Mol Imaging (2011) 38:576–591 579comitantly reduce 5-HT storage and breakdown because of
the decreased reuptake of 5-HT.
Later it appeared that 5-HT deficiency is related to other
behavioural dysfunctions like aggression and impulsivity,
while not solely deficiencies in 5-HT neurotransmission
underlie depressive symptoms. This led to the denosolog-
ization hypothesis implying that serotonergic dysfunction
may be related to dimensions of behaviour cutting across
diagnostic boundaries, and thus not necessarily show
correlations with diagnostic entities [41]. This approach
was probably systematically applied for the first time in
imaging studies by the Ghent group (head R.A. Dierckx)
through transnosological research of impulsivity using
SPECT activation studies and 5-HT2A receptor imaging in
suicidality, eating disorders and personality disorders (in
men and dogs) [42–45].
Depression has a multi-symptom pathology and may
probably be caused by flaws in several neurotransmitter
systems and molecular signalling pathways. Yet, the
serotonergic system may play an important role as it is a
modulatory system, influencing the activity of many other
neurotransmitter pathways throughout the brain.
Recent technologies: radiopharmaceuticals
for measuring serotonin synthesis
Recent technologies allow research in living animals and
humans. PET is such a noninvasive technique that enables
quantification of physiological processes by measuring tracer
kinetics. PETcan reveal the dynamics of biological processes
like 5-HT neurotransmission. In the pathway for 5-HT
synthesis, the availability of Trp determines the rate of 5-
HT formation; because the Km values of TPH and AADC
are greater than the physiological Trp concentrations, the
enzymes are not saturated [46, 47]. This means that both Trp
and 5-HTP analogues can be used for measuring 5-HT
synthesis rates. The first attempts at imaging 5-HT synthesis
were conducted by labelling natural Trp with tritium. Some
disadvantages were noted, like the incorporation of Trp into
proteins which reduces tracer availability [48, 49]. Therefore,
other tracers have been developed with more favourable
characteristics, such as α-[
11C]methyltryptophan ([
11C]AMT,






As Trp turned out to be unsuitable as a tracer, a radiolabelled
analogue of Trp was introduced for measurement of 5-HT
synthesis, α-methyltryptophan (AMT). This compound is a
substrate of TPH and will eventually be converted to α-
methylserotonin. Because α-methylserotonin is not degraded
by MAO and cannot cross the BBB, it is trapped for a long
period in the brain [50].
Preclinical data
Kinetic modelling and validation The first studies employed
AMT labelled with
3Ha n d
14C to perform autoradiography
in rats. A kinetic model for measuring [
14C]AMT uptake was
developed using a three-compartment model (or two-tissue
compartment model) with irreversible tracer trapping, the
compartments being plasma, brain and irreversibly trapped
tracer [7, 51]. The slope of the linear function depicting
distribution volume (DV) plotted against time under steady-
state conditions represents the unidirectional trapping of the
tracer indicated by the constant Ka. Subsequent studies used
AMT labelled with
11C for PET scanning in monkeys and
dogs to measure individual rate constants and to enable
Patlak analysis.
In this model, the Ka (or K complex) describes a
trapping constant that takes all individual rate constants into









In Eq. 1,K 1 resembles tracer influx into the brain, k2 is
the efflux constant and k3 the irreversible trapping constant
(Fig. 2).
To estimate physiological rates of 5-HT synthesis, Ka
must be divided by a lumped constant (LC) to correct for
difference in affinity of AMT and Trp for TPH and the
different amounts of both compounds entering the kynur-
enine pathway. The LC is on average 0.42 in rat brain [52,
53]. In this way, a K
T value can be obtained which is
further converted to 5-HT synthesis rates by multiplication
with free Trp concentrations in plasma (Cp
Trp). Thus,








Fig. 2 Three-compartment model, or two-tissue compartment model,
with irreversible tracer trapping. [
11C]AMT in plasma is transported
over the BBB into the brain, where it can be irreversibly trapped,
mainly as [
11C]AMT but also as [
11C]AM5HTP or [
11C]AM5HT. The
three compartments are plasma, precursor pool and irreversible
trapping compartment
580 Eur J Nucl Med Mol Imaging (2011) 38:576–591Ka can also be measured with a graphical method like
the Patlak plot [55]. This graphical method is not con-
strained by individual rate constants, but based on macro-
system parameters, usually resulting in less variability. The
slope of the Patlak plot represents Ka.
However, there are some contradictory results concerning
the efficiency and reliability of radiolabelled AMT. In the
first 60 min after injection, only a small fraction of
labelled AMT is converted to labelled AM5HT in the rat
brain [56]. Different research groups have obtained
significantly different results in calculating the percentage
of radioactivity corresponding to [
11C]AM5HT in the
DRN, ranging from 2–4% after 90 min in monkeys [57]t o
3 1 %a f t e r6 0m i ni nr a t s[ 7]. It has been suggested that
AMT PET measures Trp uptake in the brain rather than rates
of 5-HT synthesis [57], although Diksic and colleagues
argue that the significantly better fit of a three-compartment
model compared to a two-compartment model suggests
irreversible tracer trapping and not only the presence of
AMT in the brain [58]. The slow kinetics resulted in the
lack of a linear portion of the Patlak plot at the moment of
tracer equilibrium between reversible compartments and
plasma [57, 59]. Gharib and colleagues correctly pointed
out that AMT does not meet all the assumptions made in
the Patlak model [56]. The transfer of unmetabolized
tracer between brain and plasma is not fully reversible.
Another problem is that labelled AMT can enter the
kynurenine pathway since it is an analogue of Trp and the
activity of this pathway will increase the amount of
radioactivity which is trapped in the brain. Therefore,
Chugani and Muzik refer to the measured Ka as a
reflection of the capacity of 5-HT synthesis, rather than
the synthesis rate [59].
Although a kinetic analysis of AMT uptake may not
provide true synthesis rates, labelled AMT is sensitive
enough to detect physiological changes and may provide
more information about serotonergic neurotransmission.
Neurons stained for 5-HT or TPH were colocalized with
[
3H]AMT in the rat brain and [
3H]AMT5HT was released
from serotonergic cell bodies in the raphe nucleus and
serotonergic terminals in projection areas like the hippo-
campus and striatum. This release was increased after
d e p o l a r i z a t i o nb y5 0m MK C l ,a sc o m p a r e dt ob a s e l i n e
[60]. Studies using autoradiography revealed that the half-life
of the precursor pool in rats is approximately 20 min and
treatment with lithium results in a 52% increase of 5-HT
synthesis rates in the parietal cortex and a 47% increase in the
caudate nucleus [7, 51]. This indicates the ability of AMT to
detect changes in serotonergic neurotransmission.
Effect of pharmacological challenges Studies with
14C-
labelled AMT in experimental animals using autoradio-
graphic techniques after various interventions and brain
lesions indicated that AMT could detect changes in the
rate of 5-HT synthesis (see reviews by [31, 54]). These
pharmacological interventions revealed differences in the
acute or chronic effect of SSRIs on serotonin synthesis
rates [61, 62] that could possibly be explained by
autoreceptor stimulation.
This was also shown in a more recent study with the
SSRI citalopram (10 mg/kg per day for 14 days) in
olfactory bulbectomized (OBX) rats, a depression model.
OBX rats showed an increase of 5-HT synthesis in terminal
areas and reductions in the DRN. Chronic citalopram
reduced 5-HT synthesis to the levels of sham-operated rats
receiving citalopram in the terminal areas, and marginally
increased synthesis in the DRN. As citalopram treatment in
sham-operated rats also reduced 5-HT synthesis in some
brain areas (DRN, hippocampus), the reduction of 5-HT
synthesis in terminal areas of OBX rats may be explained
by feedback inhibition through autoreceptors [63].
Autoreceptors located on serotonergic neurons are very
important in the regulation of 5-HT synthesis and they play
a crucial role in the therapeutic action of antidepressants.
The 5-HT1A (somatodendritic receptor on cell bodies) and
5-HT1B subtypes (presynaptic receptor on nerve terminals),
regulating the feedback inhibition of 5-HT release, deserve
attention because of their role in the late onset of
therapeutic effects of many antidepressants.
Compared to the above-mentioned studies with anti-
depressants, similar effects were seen with the 5-HT1A
receptor agonist buspirone. Acute buspirone treatment of
rats (10 mg/kg, subcutaneous) significantly decreased 5-HT
synthesis rates, while chronic treatment (10 mg/kg per day
for 14 days, subcutaneous) abolished this effect [64]. This
finding is in accordance with previous results showing a
reduction of serotonergic firing rate and reduced 5-HT in
projection areas like the hippocampus [65, 66].
Less is known about the role of 5-HT1B receptors on the
nerve terminals in projection areas. The nonselective 5-
HT1B receptor agonists TFMPP and CGS12066B acutely
decrease 5-HT synthesis rates in the DRN and MRN
(probably caused by partial action on 5-HT1A receptors)
of rat brain [67]. Acute CGS12066B decreases 5-HT
synthesis rates in brain areas known to contain solely 5-
HT1B receptors (e.g. the median of the nucleus caudatus
and the nucleus accumbens) [68], while TFMPP decreases
5-HT synthesis in almost all terminal areas. Subchronic
treatment (7 days) with both compounds decreases 5-HT
synthesis in terminal areas.
The much more selective 5-HT1B receptor agonist CP-
93129 when administered acutely (7 mg/kg, i.p.) decreased
synthesis rates only in projection areas. This effect was
abolished by chronic treatment (7 mg/kg per day for 14
days, subcutaneous) which is explicable because of the
desensitization of the 5-HT1B autoreceptors [69].
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can reduce 5-HT synthesis rates in the brain, but the
receptors desensitize in response to chronic stimulation, so
that their inhibitory effects are transient.
These different effects of the pharmaceuticals are
difficult to detect by simple measurements of 5-HT
concentrations and made it clear that antidepressants have
a regional specific effect on serotonin synthesis. Eventually
effects on serotonin synthesis will influence the 5-HT
availability for release and therefore may be a very
important process in the efficacy of antidepressants. The
studies with AMT described are excellent examples of how
PET tracers can provide novel insights into physiological
processes.
The most pronounced effects of pharmacological
challenge are expected when the enzymes of the 5-HT
synthesis pathway (AADC and TPH) are directly inhibited
and this may provide information about the validity of the
method. Indeed, the TPH inhibitor p-chlorophenylalanine
(PCPA, 200 mg/kg for 3 days i.p.) and the inhibitor of
TPH activation, AGN-2979 (10 mg/kg, i.p.), both reduced
5-HT synthesis rates [70, 71]. Surprisingly, the AADC
inhibitor NSD-1015 (100 mg/kg, i.p.) appeared to increase
5-HT synthesis [72]. This discrepancy may be explained
by the additional inhibition of MAO by NSD-1015 or by
the ability of NSD-1015 to increase levels of free Trp in
plasma [73]. Therefore, results obtained with NSD-1015
should be interpreted with caution as they are probably not
solely attributable to inhibition of AADC.
Preclinical PET studies Although the above-mentioned
studies may provide important insights regarding physio-
logical processes in animals, autoradiography does not take
individual rate constants into account. Higher accuracy can
be obtained by monitoring tracer kinetics in living animals
and humans using PET. The first study using
11C-labelled
AMT for PET imaging was performed in dogs [74]. Both
oxygen and Trp increased the trapping of [
11C]AMT in dog
brain, which should be expected if [
11C]AMT trapping
reflects 5-HT synthesis. Another experiment in dogs
evaluated the time-dependent effect of 3,4-methylenediox-
ymethamphetamine (MDMA) infusion (2 mg/kg). After
1 h, 5-HT synthesis was strongly increased (up to six times
above baseline), though subsequently a decline in 5-HT
synthesis rates was observed to 50% of baseline after 5 h
[75]. This is in accordance with the observation that
MDMA first stimulates 5-HT release which leads to
increased 5-HT synthesis, but finally destroys 5-HT
terminals with a corresponding decrease of neurotransmitter
formation [76].
Interestingly, 5-HT synthesis rates measured with [
11C]
AMT PET in rhesus monkeys did not correlate with 5-
HIAA concentrations in the CSF. Whether this is due to a
lack of accuracy of the AMT method or a difficulty of
linking 5-HIAA in CSF to 5-HT synthesis within brain
remains unclear [77], although in theory, during steady state
there should be a close correlation between the conversion
of 5-HT to 5-HIAA and the elimination of 5-HIAA from
brain to CSF.
More concerns about the AMT method were raised by
the same research group as they showed that even after
3 h in rhesus monkeys no equilibrium had been reached
between tracer in plasma and tracer in reversible tissue
compartments. Therefore, the Patlak plot showed no
linear portion, which is necessary for calculation of
influx rates [57].
However, the preclinical data contributed to the
understanding of what the tracer is really measuring
and whether the tracer is valid for clinical research,
making it worthwhile to further investigate serotonin
synthesis under clinical conditions.
Clinical data
Eventually a tracer should have the ability to visualize
physiological processes in humans, in order to clarify the
pathophysiology of disease and to be employed in routine
clinical practice.
Human PET data of [
11C]AMT are modelled in
approximately the same way as canine or monkey data
(see above). However, in humans both a Patlak approach
and a two-tissue compartment model can be used, although
the value of the LC in humans is unknown. While in
animals the Patlak approach may not be valid, in humans a
steady state appears to be reached which is accompanied by
a linear portion of the Patlak plot justifying its use for
quantification purposes [78]. By comparing different
studies in humans as well as in monkeys it was found that
there was a high correlation between [
11C]AMT trapping,
[
11C]5-HTP accumulation and 5-HT concentrations deter-
mined postmortem [79].
A disadvantage of kinetic modelling is that an arterial
cannula is required for blood sampling (determination of an
arterial input function), which is a quite invasive procedure.
The use of venous radioactivity as input causes a bias in the
results with overestimation of the Ka values, but this may
be acceptable if no arterial blood samples can be taken [80].
The first study using [
11C]AMT PET focused on gender
differences and Trp depletion [78]. Both females and males
showed much lower Ka values after acute Trp depletion
through ingestion of a Trp-free amino acid mixture. The
change was about 90% in males and 95% in females. Acute
Trp depletion has been associated with lowered mood in
vulnerable subgroups and with sensitivity to stress [81–83].
At baseline women had lower levels of free Trp in plasma
582 Eur J Nucl Med Mol Imaging (2011) 38:576–591than men. Possibly due to this difference in Trp levels,
women showed lower rates of 5-HT synthesis than men at
baseline, although the Ka did not differ between genders.
The Ka should not be confused with rates of 5-HTsynthesis
which are also based on plasma levels of free Trp.
Conflicting results were reported regarding gender differ-
ences. Where Chugani et al. [84] found an increase, Sakai
et al. [21] described a decrease of the Ka in females. These
conflicting findings could be due to the different protocols
that were employed including a different nutritional and
metabolic state of the subjects.
Later studies focused on the effect of age on 5-HT
synthesis and on the examination of various pathologies
using [
11C]AMT PET (see reviews by [31, 54]).
More recent research has focused on the effect of oxygen
on 5-HT synthesis, as it is necessary for TPH activity. Even
slight hypoxia affects the metabolism of Trp, probably
because TPH has a low affinity for oxygen [85]. This is
reflected in the Ka values measured under high and low
oxygen concentrations (60 and 15% oxygen, respectively).
The increase in the measured rate of 5-HT synthesis at high
oxygen concentrations is about 50% [86], providing
evidence that [
11C]AMTcan be used for measuring changes
of TPH activity.
When clinical applications for a tracer of 5-HT
synthesis are considered, research on depressed patients
is of great interest. Changes in Patlak Ka were detectable
with [
11C]AMT PET in medication-free patients with
major depression [87]. Most obvious was the reduction
of Patlak Ka in the cingulate cortex (CC), bilaterally in
women and in the left hemisphere in men. This brain area
is involved in attention and emotion and shows abnormal-
ities of cerebral blood flow and glucose metabolism in
patients with major depression [88]. The CC receives large
projections from the DRN and MRN and projects to
orbitofrontal cortex (OFC) and amygdala, two areas
hypothesized to show dysfunction in depression. Remark-
ably, no differences in 5-HT synthesis rate were found in
the OFC or dorsolateral prefrontal cortex. This suggests
that the difference in glucose metabolism observed in
these regions may not be attributed to altered 5-HT
synthesis. Surprisingly, Ka did not correlate with the
severity of depression [87].
Treatment with the SSRI citalopram increased Ka in the
CC and this increase is associated with elevated mood as
assessed by Hamilton rating scores [89]. Other brain areas
where citalopram increased 5-HT synthesis rates are the left
and right prefrontal gyrus. These effects were not seen after
10 days, only after 24 days. This delay in the onset of
therapeutic effects of an SSRI was probably caused by a
feedback loop involving 5-HT1A autoreceptors. It is known
that blocking the 5-HT1A receptor with pindolol can
accelerate the therapeutic effects of antidepressants [90].
Indeed, at day 24 the increase in 5-HT synthesis rate
induced by an SSRI was greater in patients who received
pindolol at day 10 compared to placebo. Whether this
increase in 5-HT synthesis is due to 5-HT1A autoreceptor
blocking remains questionable, because pindolol also
excites dopaminergic and noradrenergic neurons [91]. Most
probably the total blockage of central beta-adrenoceptors by
pindolol plays an important role [92].
In addition, the binding potential of [
18F]MPPF, a 5-
HT1A receptor ligand, could not be correlated to 5-HT
synthesis rates as measured with [
11C]AMT in the raphe
nuclei [93]. However, in terminal areas of serotonergic
neurons (like hippocampus, anterior CC and anterior insula)
a negative correlation was found, indicating that decreased
binding of [
18F]MPPF to 5-HT1A heteroreceptors increased
5-HT synthesis. These studies show that a combination of
different tracers can lead to greater understanding of
processes in the human brain.
While under healthy conditions [
11C]AMT may give
estimates of 5-HT synthesis, a recent human PET study
confirmed that this tracer can actually enter the kynurenine
pathway. It was shown that brain tumours show differences
in IDO (the enzyme converting Trp to kynurenine)
expression and that this expression was related to the
amount of AMT taken up by the tumour [94].
[
11C]5-HTP
Tracer conversion to kynurenine can be prevented by
labelling the direct precursor of 5-HT, which is only
metabolized in the pathway for 5-HT synthesis. Injection
of 5-HTP labelled in the β-position can provide insight into
endogenously synthesized 5-HT, since 5-HTP is the
substrate of the last enzyme involved in the production of
5-HT. [
11C]5-HTP will undergo the same conversions as 5-
HTP and will eventually end up as [
11C]5-HIAA (Fig. 3).
Because of the difficulty of labelling 5-HTP in the β-
position with
11C, a procedure which involves rapid
enzymatic steps, this radiotracer has only been synthesized
in a few imaging institutions [5, 95].
Neuroendocrine tumour imaging
[
11C]5-HTP is mainly used for the detection of neuroendo-
crine tumours and not for brain imaging. These tumours are
usually slowly growing, highly differentiated and may have
various characteristics, although active uptake and decar-
boxylation of monoamine precursors like L-dopa and 5-
HTP and overproduction of hormones are typical. Conven-
tionally used metabolic PET tracers, like [
18F]FDG,
appeared unsuitable for the detection of neuroendocrine
tumours, whereas detection of the uptake of monoamine
precursors with [
11C]5-HTP PET resulted in the visualiza-
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diagnostic sensitivity of pancreatic islet cell tumours greatly
benefits from [
11C]5-HTP PET in combination with a CT
scan, while carcinoid tumours are better visualized with
[
18F]FDOPA, a radiolabelled analogue of the precursor of
dopamine [96].
However, a problem in this detection method is the high
urinary concentration of
11C, caused by excretion of radio-
labelled 5-HIAA. Inhibition of peripheral decarboxylase
activity by administering the AADC inhibitor carbidopa
reduces the excretion of
11C and increases tracer uptake in
the tumours [97, 98]. The effects of carbidopa on tracer
uptake have also been investigated in a xenograft model of
neuroendocrine pancreatic tumours by Neels and colleagues
[99]. Carbidopa improved tumour imaging also in this
animal model, probably by inhibiting peripheral AADC
activity and increasing availability of the tracer.
Preclinical data
In 1992, an initial preclinical study with [
11C]5-HTP for
measuring cerebral 5-HT synthesis was performed in rhesus
monkeys [100]. The authors used a reference area in the
brain for modelling the time-activity curves of other brain
areas, in order to analyse tracer kinetics. In this model the
rate constant k3 represents irreversible tracer trapping
(Figs. 2 and 3).
Since blockingof specificenzymatic steps inthe metabolic
pathway had the expected effects, [
11C]5-HTP appeared to be
a valid tracer for measurement of the rate of decarboxylation
of 5-HTP to 5-HT. Blocking central AADC with NSD-1015
resulted in a decrease of the rate constant k3 in both monkeys
and rats. This constant reflects 5-HTP decarboxylation and
mirrors 5-HT synthesis. The nonspecific blocking of MAO
with pargyline (2 days 2 × 4 mg/kg) or the selective blocking
of MAO-A with clorgyline (0.2 mg/kg) did not change the
rate constant indicating that radiolabelled 5-HIAA does not
readily leave the brain [100, 101]. Especially in the striatum,
levels of radioactivity were high and the value of k3 was
influenced by the concentration of pyridoxine or vitamin B6,
t h ec o f a c t o ro fA A D C[ 102].
Not only 5-HTP is a substrate of AADC, but also L-
dopa, the precursor of dopamine. The affinity of AADC for
5-HTP is probably higher than for L-dopa [103]. When
unlabelled substrates were administered to increase the size
of the endogenous pools, the measured value of k3 was
decreased. This indicates a limited capacity of the enzyme
for substrate conversion and saturation of the decarboxyl-
ation reaction [103]. The detriment of [
11C]5-HTP is that
AADC is not only present in serotonergic but also in
Fig. 3 Metabolism of [
11C]5-HTP. Most of 5-HT synthesis takes
place in the terminal areas. Tryptophan is acquired through the diet
and is transported across the blood-brain barrier (BBB) by the large
amino acid transporter (LAT). Within neurons Trp is catabolized by
tryptophan hydroxylase (TPH) to 5-HTP. Subsequently, 5-HTP is
converted to 5-HT by AADC. PCPA and NSD 1015 can block TPH
and AADC, respectively. 5-HT is taken up and stored in vesicles by
the vesicular monoamine transporter (VMAT). When neurons fire, the
vesicles fuse with the synaptic membrane whereafter 5-HT is released
within the synaptic cleft. The serotonin transporter (SERT) causes
reuptake of 5-HT that can either be restored into vesicles or be broken
down by monoamine oxidase (MAO) to 5-HIAA. Eventually, 5-HIAA
is released into the bloodstream and excreted by the kidneys. A similar
process takes place in peripheral organs. Radiolabelled 5-HTP under-
goes the same conversions as endogenous 5-HTP and is therefore a
suitable tracer for 5-HT synthesis. A two-tissue compartment model
with irreversible tracer trapping can be used for modelling [
11C]5-HTP
kinetics. The rate constant for transport from plasma to brain is
indicated by K1, k2 represents efflux of the tracer back into the
bloodstream and k3 is the irreversible trapping constant
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the tracer in these neurons as well [103, 104].
The only experiments with [
11C]5-HTP in rodents were
performed by Lindner and colleagues [101]. PET imaging
was not performed in this study, but animals were
sacrificed 40 min after tracer injection and high-
performance liquid chromatography (HPLC) was used to
separate [
11C]5-HTP from its metabolites in brain extracts.
At 40 min after injection, 95% of the radioactivity within




11C]5-HIAA, the latter compound comprising 75% of
total brain radioactivity. These data indicated an extensive
metabolism of [
11C]5-HTP in the 5-HT synthesis pathway.
Less than 5% of the cerebral radioactivity was related to
other metabolites. By blocking the enzyme MAO, the
fraction of 5-HT in the striatum was increased, which
could be expected if MAO degrades 5-HT. Blocking of
central AADC by NSD-1015 decreased the conversion of
5-HTP to 5-HT and 5-HIAA, while the blocking of
peripheral AADC with carbidopa increased the brain
uptake of 5-HTP, although it decreased the formation of
5-HIAA. Surprisingly, carbidopa increased k3 in the
striatum indicating increased turnover of the tracer, but it
lowered k3 in the cerebellum. The underlying mechanism
is unclear.
Most of the above-mentioned research was performed
with a reference tissue analysis or with HPLC rather than
PET. HPLC can be used in preclinical research, but PET
offers opportunities to visualize the living brain in humans.
The most accurate way of determining tracer uptake in
tissue is to relate this to plasma input, instead of using a
reference tissue. An input function derived from arterial
blood samples can be used to model time-activity curves in
brain to characterize the cerebral kinetics of the tracer. The
most suitable model for analysis of the kinetics of [
11C]5-
HTP is a two-tissue compartment model with irreversible
tracer trapping (Fig. 3). This model is approximately the
same as for [
11C]AMT. The individual rate constants for
tracer uptake (K1), tracer efflux (k2) and irreversible tracer
trapping (k3) can be used for calculating the accumulation
constant Kacc (see Eq. 1).
This model appears to be valid in the rhesus monkey, as
it could detect changes in AADC activity after pharmaco-
logical manipulation, and elimination of [
11C]5-HIAA was
negligible within a scan time of 60 min [105].
In another study [106], the authors compared the
ability of the PET tracers [
11C]5-HTP and [
11C]AMT to
measure AADC activity in the monkey brain. It appeared
that these tracers had different rate constants and accumu-
lation rates. While [
11C]AMT showed higher uptake of
radioactivity in the brain, which is not surprising because
less [
11C]5-HTP than [
11C]AMT is available in plasma,
the values of K1,k 3 and Kacc in striatum and thalamus
were lower. The reason for a lower availability of [
11C]5-
HTP could be extensive decarboxylation of this tracer by
AADC in peripheral organs. Remarkable is the fact that
although 5-HT concentrations differ highly between
different brain areas, the trapping of [
11C]AMT is rather




To the best of our knowledge, the first PETstudy with [
11C]
5-HTP in the human brain was performed in 1991 [107].
Patients suffering from major depression showed a reduced
uptake of the tracer in their brains. A recent clinical study
reported a relationship between [
11C]5-HTP trapping and
mood states [108]. A clear negative correlation was
observed between the cardinal symptoms of premenstrual
dysphoria in women, like irritability and depressed mood,
and changes in tracer trapping in the entire brain (Fig. 4),
prefrontal regions and some regions of the striatum. The
opposite mood states, feelings of happiness and mental
energy, showed a strong positive correlation with tracer
trapping. The same two-tissue compartment model as was
used for monkeys has been employed for PET studies of 5-
HTsynthesis in the human brain [109]. Tracer influx should
never be rate limiting or it will lower the k3. Hagberg and
colleagues found a distribution volume above zero, indi-
cating considerable tracer uptake in the brain. The constant
that takes the distribution volume into account is the net
accumulation rate constant Kacc, which is referred to as Ka
in [
11C]AMT PET.
There are only a few published reports on the use of
[
11C]5-HTP for imaging 5-HT synthesis, and thus there are
many opportunities for clinical studies with this tracer. The
correlation of tracer trapping with mood indicates that this
method may be useful for assessing the therapeutic efficacy
of antidepressants. Other pathological conditions may be
elucidated using [
11C]5-HTP PET, such as the role of
serotonergic dysfunction in eating disorders.
Discussion
The serotonergic system is complex, influencing many
other neurotransmitter systems and behavioural functions.
Monitoring 5-HT synthesis or other elements of serotoner-
gic neurotransmission in vivo with PET gives insight into
what is going on in the living brain. Research reviewed
here shows the possibilities of this technique to elucidate
processes otherwise not fully understood. However, refine-
ment is necessary to increase resolution and increase target
to background ratios. In addition, many elements of the 5-
HT system have not yet been visualized, making the picture
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multiple tracers could be used, visualizing different aspects
of serotonergic neurotransmission like receptor binding
potential and 5-HT synthesis.
A dynamic process such as 5-HT synthesis cannot
reliably be assessed by single time point measurements of
5-HT and its metabolites in CSF or blood platelets. Since 5-
HT synthesis is one of the initial processes in serotonergic
neurotransmission and a crucial determinant of 5-HT-
mediated signal transduction, quantification of this process
by PET is of great interest. Two tracers, [
11C]5-HTP and
[
11C]AMT, have been developed for this purpose, which
have distinct advantages and disadvantages.
A specific tracer that measures 5-HT synthesis rates may
answer some of the questions about changes of 5-HT
synthesis in different physiological or pathological con-
ditions. Most important results show the effects of
antidepressants on 5-HT synthesis through activation of
autoreceptors, which may indicate a crucial role for 5-HT
synthesis in the efficacy of antidepressants. This should be
elucidated in future research.
As outlined above, more research has been done with
[
11C]AMT than with [
11C]5-HTP, probably because pro-
ducing [
11C]5-HTP is difficult, requiring several enzymatic
steps [110]. At the moment it is only produced in four to
five centres all over the world.
The most striking difference between the results of AMT
and HTP studies concerns the effect of Trp depletion and its
correlation with mood states. While [
11C]AMT detects a
large decrease in 5-HT synthesis rates after acute Trp
depletion, [
11C]5-HTP does not [78, 111]. The opposite
accounts for mood states; no correlation was found between
[
11C]AMT radioactivity in the brain and Hamilton scores,
whereas the brain uptake of [
11C]5-HTP is correlated with
different mood states [87, 108]. The different results
obtained with [
11C]5-HTP and [
11C]AMT may be due to
the fact that 5-HTP and AMT are substrates for different
enzymes, AADC and TPH, respectively. The tracers may
measure different aspects of Trp metabolism and 5-HT





11C]AMT kinetics is very slow, resulting in a low
production of [
11C]AM5HT and a high fraction of
trapped tracer representing [
11C]AMT (parent) [56].
& AMT is an analogue of Trp which behaves differently
than the natural amino acid (Fig. 5).
& In rats and monkeys, equilibrium between irreversible
compartments and plasma is not reached within a PET
time scale. As a consequence of this, Patlak modelling
produces erroneous results [56, 57].
& In contrast to [
11C]5-HTP, [
11C]AMT can enter the
kynurenine pathway since it is an analogue of Trp. This
route becomes important under inflammatory conditions
and it may cause difficulties in the interpretation of
[
11C]AMT scan data [94].




11C( indicated in blue) is incorporated in the β-position
of the carbon skeleton of 5-HTP, but in the methyl group of AMT
Fig. 4 Mood correlates with
[
11C]5-HTP trapping. Both pos-
itive and negative mood states
are related to the amount of
tracer trapping in the brain of
women with premenstrual dys-
phoria. Especially irritability,
depression, energy and happi-
ness show strong correlations
with rs. VAS visual analogue
scale, rs rate for [
11C]5-HTP
irreversible trapping. Reprinted
from [108], with permission
from Elsevier
586 Eur J Nucl Med Mol Imaging (2011) 38:576–591Results obtained with [
11C]AMT under pathological
conditions may reflect activation of the kynurenine pathway
rather than 5-HT synthesis. Because 5-HTP is the endog-
enous direct precursor of 5-HT its metabolic fate is much
less complex (Fig. 5), even though AADC is also present in
dopaminergic neurons to convert L-dopa into dopamine.
After oral administration of 5-HTP in rats, the immuno-
reactivity of 5-HT and 5-HTP colocalized in the raphe
nuclei, but also in the dopaminergic neurons in the
substantia nigra pars compacta. This suggests that [
11C]
5-HTP could also be converted to ectopic [
11C]5-HT in
dopaminergic neurons [112].
Thus, based upon these considerations we would prefer
[
11C]5-HTP PET for the study of alterations of 5-HT
synthesis in different pathological conditions.
However, some prerequisites of the model used for
calculating 5-HT synthesis rates with [
11C]5-HTP should be
mentioned. Erroneous data can be obtained if the biological
system does not meet the following conditions:
& AADC must operate far from saturation, so that changes
in the rate of 5-HT formation can be measured. This
condition is probably met, because the tissue concen-
tration of 5-HTP is below the Michaelis-Menten
constant of AADC. However, the enzyme may ap-
proach saturation under conditions where 5-HT synthe-
sis is strongly increased [103].
& 5-HIAA should not leave the brain within the time span
of the scan. This metabolite is finally excreted, but
MAO inhibition does not affect k3 indicating that within
a 60-min scan the loss of radiolabelled 5-HIAA from
brain tissue is negligible [100].
& 5-HIAA from the blood should not contribute to
measured radioactivity in the brain. 5-HTP is converted
to 5-HT and 5-HIAA in peripheral organs. Although 5-
HT cannot be transported across the BBB, 5-HIAA can.
However, plasma concentrations of 5-HIAA are only
large at the end of the scanning period and MAO
inhibition does not change the k3. Therefore, the
contribution of 5-HIAA in the circulation to cerebral
radioactivity is probably minor.
& Enough tracer should enter the brain as the amount of
tracer should not be rate limiting. Therefore, the
cerebral distribution volume must be above zero, as
indicated by Hagberg and colleagues [109]. The
delivery of [
11C]5-HTP to the brain could be facilitated
by intraperitoneal administration of carbidopa [99].
& Synaptic transport of Trp and 5-HTP should be limited
to 5-HT neurons and AADC should be specific for 5-
HTP. Although L-dopa is also a substrate of AADC, it
seems to influence [
11C]5-HTP trapping to a lesser
extent than cold 5-HTP, indicating that 5-HTP may be
predominantly used by serotonergic neurons [103].
Most of these prerequisites have been investigated in
humans and monkeys and the conditions for modelling
[
11C]5-HTP kinetics seem to be met in these species, but
tracer validation for microPET studies in rodents has not
yet been performed. [
11C]5-HTP scans in rodents could be
used in preclinical testing of the effects of antidepressants
and provide new insight into the pathophysiology of
disease. Future research should indicate whether [
11C]
5-HTP and [
11C]AMT measure enzymatic activity (TPH,
AADC, IDO) or the true rates of 5-HT synthesis.
The above-named prerequisites of measuring 5-HT
synthesis with [
11C]5-HTP and the fact that [
11C]AMT is
not an ideal tracer for this purpose emphasize the complexity
of measuring 5-HT synthesis. Although most properties of
[
11C]5-HTP seem appropriate, the difficult production of this
radiopharmaceutical limits its widespread application. Future
research should concentrate on elucidating what [
11C]5-HTP
is exactly measuring and improving tracer properties.
Attempts to develop a novel tracer with improved
properties should focus on: (1) specific uptake of the
tracer by serotonergic neurons, (2) chemical modification
of the radiopharmaceutical so that it is no longer
converted to a 5-HIAA analogue and (3) a simplified
production process.
Conclusion
We have reviewed several techniques for the evaluation of
serotonin synthesis. PET can directly visualize this physi-
ological process, whereas other techniques can only provide
an indirect measurement. This makes it a valuable tool in
clinical research especially because results indicate that
serotonin synthesis seems to play a role in depression and
antidepressant action, although widespread application of
[
11C]5-HTP and [
11C]AMT in clinical research is not
possible yet.
A unified theory of affective disorders can only be
achieved if we consider different imaging methods and also
take into account both animal and human histological data.
In the future it may be worthwhile to develop the tools to
study both receptor density and 5-HT synthesis, and this
will hopefully yield a better and more complete under-
standing of the processes involved in the pathophysiology
of affective disorders.
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